# Paliperidone

## Invega inj 100mg \(=156mg\)

| 藥物代碼 | IINV |
| :--- | :--- |
| 適應症 | Acute & maintenance treatment of schizophrenia in adults. |
| 副作用 | Cerebrovascular events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM, wt gain, hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures, dysphagia, suicide, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions, somnolence/sedation, dizziness, akathisia & extrapyramidal disorder. |
| 禁忌 | Hypersensitivity to paliperidone or risperidone. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen, adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle \(the 39 mg dose was not studied in schizoaffective disorder trials\). The monthly maintenance dose may be administered 7 days before or after the monthly time point. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Invega 3mg extended release

| 藥物代碼 | OINV |
| :--- | :--- |
| 適應症 | Treatment of schizophrenia. |
| 副作用 | Cardiac disturbances, arrhythmia, GI disturbances, upper abdominal pain, extrapyramidal disorder, weight increase. Rarely edema, hypersensitivity reactions, dystonia, hypotension, venous thromboembolism.Cardiovascular: Tachycardia \(16% geriatric \)Endocrine metabolic: Hyperprolactinemia \(geriatric, 45% to 49% \), Weight gain \(4% to 9% \)Gastrointestinal: Constipation \(4% to 5% \), Indigestion \(5% to 6% \)Neurologic: Akathisia \(3% to 10% \), Extrapyramidal disease \(2% to 20% \), Somnolence \(6% to 12% \)Respiratory: Nasopharyngitis \(2% to 5% \) |
| 禁忌 | Hypersensitivity to risperidone. Congenital long QT syndrome, cardiac arrhythmias. Pre-existing severe GI narrowing. Lactation. |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

